Hepatitis D Treatments

Find Hepatitis D Treatments

Generic Name

Lamivudine

Brand Names

Abacavir, Cimduo, Combivir, Delstrigo, Dovato, Efavirenz, Epivir, SYMFI, Triumeq

FDA approval date: October 04, 2010

Classification: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Form: Tablet, Kit, Solution

What is Abacavir (Lamivudine)?

Abacavir and lamivudine tablet, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 infection.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Who is this study for: Patients with KSHV inflammatory cytokine syndrome

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Other, Drug

Study Drugs: Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab

Study Phase: Phase 2

Background: \- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People with KICS may also be at risk of getting other cancers associated with KSHV. These cancers include Kaposi sarcoma and lymp...

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of Efavirenz in Patients With Creutzfeldt-Jakob Disease

Enrollment Status: Recruiting

Publish Date: September 03, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of efavirenz in patients with Creutzfeldt-Jakob disease (CJD). A total of 246 eligible participants will be enrolled across 21 study centers nationwide. Participants will be randomly assigned in a 1:1 ratio to receive either efavirenz or placebo. Participa...

Effect of CYP2B6 Genotype and Efavirenz on the Disposition and Pharmacodynamic of Methadone and Tizanidine in Healthy Volunteers

Enrollment Status: Recruiting

Publish Date: August 20, 2026

Intervention Type: Drug

Study Phase: Early Phase 1

Summary: The main goal of this clinical study is to test how CYP2B6 genetic variations and efavirenz (cornerstone in HIV-1 therapy) dictate the disposition (PK) of CYP2B6 substrate (methadone) and PK and effect (PD) of CYP1A2 substrate (tizanidine). Specifically, the investigators will test whether efavirenz produces CYP2B6 genotype dependent unanticipated DDIs with CYP2B6 (methadone) and CYP1A2 (tizanidin...

View All Clinical Trials